Trending NewsTrending NewsNYSE:COR Cencora (COR) Stock Price, News & Analysis $333.38 -6.30 (-1.85%) Closing price 11/6/2026 03:59 PM EasternExtended Trading$333.54 +0.16 (+0.05%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cencora Stock (NYSE:COR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cencora alerts:Sign Up Key Stats Today's Range$332.67▼$338.5450-Day Range$300.71▼$354.2052-Week Range$244.82▼$377.54Volume1.68 million shsAverage Volume1.38 million shsMarket Capitalization$63.62 billionP/E Ratio18.60Dividend Yield0.72%Price Target$368.73Consensus RatingModerate Buy Company Overview Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments. Cencora serves customers in the United States and internationally. The company adopted the Cencora name in 2023, reflecting its global reach and its role across the pharmaceutical supply chain.AI Generated. May Contain Errors. Read More Cencora Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreCOR MarketRank™: 4.642857142855 of 5 starsCencora scored higher than 93% of companies evaluated by MarketBeat, and ranked 17th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingCencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on no strong buy ratings, 13 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialCencora has a consensus price target of $368.73, representing about 10.6% upside from its current price of $333.38.Amount of Analyst CoverageCencora has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cencora's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.32% Earnings GrowthEarnings for Cencora are expected to grow by 10.32% in the coming year, from $19.58 to $21.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cencora is 18.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Cencora is 18.56, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.57.Price to Earnings Growth RatioCencora has a PEG Ratio of 1.73. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCencora has a P/B Ratio of 17.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.07% of the float of Cencora has been sold short.Short Interest Ratio / Days to CoverCencora has a short interest ratio ("days to cover") of 3.43, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cencora has recently increased by 0.32%, indicating that investor sentiment is decreasing. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldCencora has a dividend yield of 0.72%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthCencora has been increasing its dividend for 15 years.Dividend CoverageThe dividend payout ratio of Cencora is 13.39%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Cencora will have a dividend payout ratio of 11.11% next year. This indicates that Cencora will be able to sustain or increase its dividend.Read more about Cencora's dividend. News and Social Media4.2 / 5News Sentiment0.68 News SentimentCencora has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 40 news articles for Cencora this week, compared to 7 articles on an average week.Search Interest22 people have searched for COR on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows9 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cencora insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,662,556.00 in company stock.Percentage Held by Insiders0.38% of the stock of Cencora is held by insiders.Percentage Held by Institutions97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cencora's insider trading history. Receive COR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COR Stock News HeadlinesDoes Earnings Beat Change The Bull Case For Cencora (COR)?November 5 at 9:33 PM | finance.yahoo.comCencora (COR) Drops 4% While Rival Cardinal Health Posts a BeatNovember 5 at 4:32 PM | 247wallst.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit. | Behind the Markets (Ad)Cencora (COR) Drops 5.2% After-Hours as Cardinal Health Reports EarningsNovember 5 at 4:32 PM | 247wallst.comCencora Earnings Call Highlights Specialty Growth and HeadwindsNovember 4, 2026 | tipranks.comCencora (COR) Reshapes Its Reporting Structure for Fiscal 2027November 4, 2026 | 247wallst.comCencora outlines $19.40-$19.75 fiscal 2027 EPS as it reshapes reporting into two segmentsNovember 4, 2026 | seekingalpha.comCencora’s (NYSE: COR) Q3 CY2026 earnings results: revenue in line with expectationsNovember 4, 2026 | msn.comSee More Headlines COR Stock Analysis - Frequently Asked Questions How have COR shares performed this year? Cencora's stock was trading at $338.07 at the start of the year. Since then, COR stock has decreased by 1.4% and is now trading at $333.3810. How were Cencora's earnings last quarter? Cencora, Inc. (NYSE:COR) released its earnings results on Wednesday, November, 4th. The company reported $4.66 EPS for the quarter, beating analysts' consensus estimates of $4.58 by $0.08. The company's quarterly revenue was up 5.5% on a year-over-year basis. Read the conference call transcript. Is Cencora buying back stock? Cencora's board authorized a share repurchase program on Thursday, May 21st 2026, which permits the company to repurchase $2 billion in shares, according to EventVestor. This means that the company could repurchase up to 3.9% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its shares are undervalued. Does Cencora have any subsidiaries? Cencora subsidiaries include these companies: Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and others. Who are Cencora's major shareholders? Cencora's top institutional shareholders include Mawer Investment Management Ltd. (0.72%), Sumitomo Mitsui Trust Group Inc. (0.53%), Beutel Goodman & Co Ltd. (0.34%) and Fort Washington Investment Advisors Inc. OH (0.23%). Insiders that own company stock include Walgreens Boots Alliance, Inc, Steven H Collis, Robert P Mauch, Robert P Mauch, Dermot Mark Durcan, Lazarus Krikorian, Elizabeth S Campbell, Silvana Battaglia, Gina Clark, Gina Clark, Leslie E Donato, Leslie E Donato and Lauren M Tyler. View institutional ownership trends. How do I buy shares of Cencora? Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cencora own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include NVIDIA (NVDA), AbbVie (ABBV), CVS Health (CVS), JPMorgan Chase & Co. (JPM), Visa (V), Walt Disney (DIS) and Johnson & Johnson (JNJ). Company Calendar Record date for 8/31 Dividend8/14/2026Ex-Dividend for 8/31 Dividend8/14/2026Dividend Payable8/31/2026Last Earnings11/04/2026Today11/08/2026Record date for 11/30 Dividend11/13/2026Ex-Dividend for 11/30 Dividend11/13/20268th Annual Healthcare Symposium11/13/2026Dividend Payable11/30/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 COR's financial health is in the Green zone, according to TradeSmith. COR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Distributors Current SymbolNYSE:COR CIK1140859 Webwww.cencora.com Phone(610) 727-7000Fax800-640-5221Employees51,000Year Founded2001Price Target and Rating Average Price Target for Cencora$368.73 High Price Target$405.00 Low Price Target$310.00 Potential Upside/Downside+10.6%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$17.92 Trailing P/E Ratio18.60 Forward P/E Ratio15.43 P/E Growth1.73Net Income$1.55 billion Net Margins1.03% Pretax Margin1.36% Return on Equity110.72% Return on Assets4.22% Debt Debt-to-Equity Ratio3.01 Current Ratio0.94 Quick Ratio0.58 Sales & Book Value Annual Sales$337.40 billion Price / Sales0.19 Cash Flow$25.05 per share Price / Cash Flow13.31 Book Value$19.29 per share Price / Book17.28Miscellaneous Outstanding Shares190,830,000Free Float190,102,000Market Cap$63.62 billion OptionableOptionable Beta0.58 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:COR) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cencora, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cencora With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
